Wire Stories
BeiGene Announces Approval in Canada of BRUKINSA� (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma
Second approval for BTK Inhibitor BRUKINSA in Canada CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–$BGNE #BTKi–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven...